enGene Therapeutics Inc. (ENGN) stock
ENGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends October 31Also trades as ENGNW
$2.41+0.13 (+5.70%)
Close on Nov 13, 2026Market cap $161.51MP/E –Yield 0.00%
enGene Therapeutics EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
For fiscal 2025 it was $2.29, up 56.8% from the year before.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $2.29 | +56.8% |
| FY2024 | Oct 31, 2024 | $1.46 | -99.0% |
| FY2023 | Oct 31, 2023 | $151.22 | +241.4% |
| FY2022 | Oct 31, 2022 | $44.30 | – |
Quarterly eps
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jul 31, 2026 | -$0.47 | – |
| Q2 FY2026CQ1 2026 | Apr 30, 2026 | -$0.43 | -189.6% |
| Q1 FY2026CQ4 2025 | Jan 31, 2026 | $0.44 | +37.5% |
| Q3 FY2025CQ2 2025 | Jul 31, 2025 | -$0.57 | -250.0% |
| Q2 FY2025CQ1 2025 | Apr 30, 2025 | -$0.51 | -210.9% |
| Q1 FY2025CQ4 2024 | Jan 31, 2025 | $0.48 | -94.4% |
| Q3 FY2024CQ2 2024 | Jul 31, 2024 | $0.32 | -96.6% |
| Q2 FY2024CQ1 2024 | Apr 30, 2024 | $0.38 | -97.1% |
| Q1 FY2024CQ4 2023 | Jan 31, 2024 | $0.46 | – |
| Q3 FY2023CQ2 2023 | Jul 31, 2023 | $8.55 | – |
| Q2 FY2023CQ1 2023 | Apr 30, 2023 | $9.30 | – |
| Q1 FY2023CQ4 2022 | Jan 31, 2023 | $13.29 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?